| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 18:38:54 UTC |
|---|
| Update Date | 2021-09-26 23:14:06 UTC |
|---|
| HMDB ID | HMDB0257622 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate |
|---|
| Description | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate, also known as {2,15-dimethyl-14-oxotetracyclo[8.7.0.0,.0,]heptadecan-5-yl}oxidanesulphonate, belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton. Based on a literature review a significant number of articles have been published on [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate. This compound has been identified in human blood as reported by (PMID: 31557052 ). [(3s,8r,9s,10s,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CC12CCC3C(CCC4CC(CCC34C)OS(O)(=O)=O)C1CCC2=O InChI=1S/C19H30O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h12-16H,3-11H2,1-2H3,(H,21,22,23) |
|---|
| Synonyms | | Value | Source |
|---|
| [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfuric acid | Generator | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulphate | Generator | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulphuric acid | Generator | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0,.0,]heptadecan-5-yl}oxidanesulfonate | HMDB | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0,.0,]heptadecan-5-yl}oxidanesulphonate | HMDB | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0,.0,]heptadecan-5-yl}oxidanesulphonic acid | HMDB | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl}oxidanesulfonate | HMDB | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl}oxidanesulphonate | HMDB | | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl}oxidanesulphonic acid | HMDB |
|
|---|
| Chemical Formula | C19H30O5S |
|---|
| Average Molecular Weight | 370.5 |
|---|
| Monoisotopic Molecular Weight | 370.18139524 |
|---|
| IUPAC Name | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl}oxidanesulfonic acid |
|---|
| Traditional Name | {2,15-dimethyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-yl}oxidanesulfonic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC12CCC3C(CCC4CC(CCC34C)OS(O)(=O)=O)C1CCC2=O |
|---|
| InChI Identifier | InChI=1S/C19H30O5S/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18/h12-16H,3-11H2,1-2H3,(H,21,22,23) |
|---|
| InChI Key | ZMITXKRGXGRMKS-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Sulfated steroids |
|---|
| Direct Parent | Sulfated steroids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Sulfated steroid skeleton
- Androstane-skeleton
- 17-oxosteroid
- Oxosteroid
- Sulfuric acid ester
- Sulfuric acid monoester
- Sulfate-ester
- Alkyl sulfate
- Organic sulfuric acid or derivatives
- Ketone
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organic oxygen compound
- Carbonyl group
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 6.77 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 17.9211 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.82 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2830.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 447.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 220.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 198.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 586.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 719.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 806.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 91.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1391.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 511.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1684.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 385.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 474.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 295.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 379.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 48.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized| Metabolite | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate | CC12CCC3C(CCC4CC(CCC34C)OS(O)(=O)=O)C1CCC2=O | 3532.2 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate | CC12CCC3C(CCC4CC(CCC34C)OS(O)(=O)=O)C1CCC2=O | 2574.4 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate | CC12CCC3C(CCC4CC(CCC34C)OS(O)(=O)=O)C1CCC2=O | 3126.8 | Semi standard non polar | 33892256 |
Derivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CCC2=O | 3118.2 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CCC2=O | 2983.9 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CCC2=O | 3721.3 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C | 3099.9 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C | 2812.2 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C | 3771.0 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C | 3117.6 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C | 3033.0 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C | 3701.8 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CCC2=O | 3345.7 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CCC2=O | 3304.3 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CCC2=O | 3843.6 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3364.0 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3078.0 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,1TBDMS,isomer #2 | CC12CCC3C(CCC4CC(OS(=O)(=O)O)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3920.7 | Standard polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3571.7 | Semi standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3571.1 | Standard non polar | 33892256 | | [(3S,8R,9S,10S,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] hydrogen sulfate,2TBDMS,isomer #1 | CC12CCC3C(CCC4CC(OS(=O)(=O)O[Si](C)(C)C(C)(C)C)CCC43C)C1CC=C2O[Si](C)(C)C(C)(C)C | 3879.8 | Standard polar | 33892256 |
|
|---|